(USPH) US Physicalrapy - Overview

Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 1.163m USD | Total Return: 12.8% in 12m

Physical Therapy, Injury Prevention
Total Rating 38
Safety 77
Buy Signal -0.19
Medical Care Facilities
Industry Rotation: -7.7
Market Cap: 1.16B
Avg Turnover: 10.6M USD
ATR: 3.37%
Peers RS (IBD): 28.9
Risk 5d forecast
Volatility30.6%
Rel. Tail Risk-9.59%
Reward TTM
Sharpe Ratio0.43
Alpha-15.33
Character TTM
Beta0.873
Beta Downside0.811
Drawdowns 3y
Max DD45.32%
CAGR/Max DD-0.16
EPS (Earnings per Share) EPS (Earnings per Share) of USPH over the last years for every Quarter: "2021-03": 0.64, "2021-06": 0.96, "2021-09": 0.85, "2021-12": 0.72, "2022-03": 0.65, "2022-06": 0.9, "2022-09": 0.58, "2022-12": 0.58, "2023-03": 0.59, "2023-06": 0.76, "2023-09": 0.62, "2023-12": 0.59, "2024-03": 0.51, "2024-06": 0.73, "2024-09": 0.69, "2024-12": 0.51, "2025-03": 0.48, "2025-06": 0.81, "2025-09": 0.66, "2025-12": 0.67,
EPS CAGR: 0.81%
EPS Trend: -11.2%
Last SUE: -0.04
Qual. Beats: 0
Revenue Revenue of USPH over the last years for every Quarter: 2021-03: 112.368, 2021-06: 126.928, 2021-09: 125.893, 2021-12: 129.833, 2022-03: 131.704, 2022-06: 140.656, 2022-09: 139.602, 2022-12: 141.182, 2023-03: 148.509, 2023-06: 151.485, 2023-09: 150.007, 2023-12: 154.801, 2024-03: 155.675, 2024-06: 167.19, 2024-09: 168.033, 2024-12: 180.447, 2025-03: 152.547, 2025-06: 164.183, 2025-09: 164.024, 2025-12: 202.726,
Rev. CAGR: 12.19%
Rev. Trend: 86.3%
Last SUE: 0.20
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: USPH US Physicalrapy

US Physical Therapy Inc. (USPH) operates outpatient physical therapy clinics. The company generates revenue through two segments: Physical Therapy Operations and Industrial Injury Prevention Services. This business model is common in the healthcare services sector, which focuses on providing direct patient care.

The Physical Therapy Operations segment addresses a range of conditions, including orthopedic, sports, and neurological injuries, as well as post-operative and preventative care. The Industrial Injury Prevention Services segment offers onsite rehabilitation, performance optimization, and ergonomic assessments for corporate clients. This segment often involves long-term contracts with large corporations.

Founded in 1990 and based in Houston, Texas, USPH is categorized under the Health Care Facilities GICS Sub Industry. To understand USPHs financial performance and competitive landscape, further research on ValueRay is recommended.

Headlines to Watch Out For
  • Outpatient clinic volume impacts physical therapy revenue
  • Industrial injury prevention contracts drive service growth
  • Healthcare reimbursement rates affect profitability
  • Labor costs for therapists influence margins
  • Regulatory changes in healthcare present operational risks
Piotroski VR‑10 (Strict) 4.5
Net Income: 15.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.58 > 1.0
NWC/Revenue: 0.14% < 20% (prev 3.17%; Δ -3.03% < -1%)
CFO/TA 0.06 > 3% & CFO 75.1m > Net Income 15.4m
Net Debt (390.2m) to EBITDA (109.7m): 3.56 < 3
Current Ratio: 1.01 > 1.5 & < 3
Outstanding Shares: last quarter (15.2m) vs 12m ago 0.74% < -2%
Gross Margin: 22.16% > 18% (prev 0.19%; Δ 2.20k% > 0.5%)
Asset Turnover: 57.64% > 50% (prev 57.50%; Δ 0.14% > 0%)
Interest Coverage Ratio: 9.23 > 6 (EBITDA TTM 109.7m / Interest Expense TTM 9.46m)
Altman Z'' 1.67
A: 0.00 (Total Current Assets 140.0m - Total Current Liabilities 139.0m) / Total Assets 1.20b
B: 0.19 (Retained Earnings 227.2m / Total Assets 1.20b)
C: 0.07 (EBIT TTM 87.3m / Avg Total Assets 1.19b)
D: 0.53 (Book Value of Equity 228.1m / Total Liabilities 433.8m)
Altman-Z'' Score: 1.67 = BB
Beneish M -3.49
DSRI: 0.74 (Receivables 64.2m/85.7m, Revenue 683.5m/671.3m)
GMI: 0.84 (GM 22.16% / 18.63%)
AQI: 0.89 (AQ_t 0.66 / AQ_t-1 0.74)
SGI: 1.02 (Revenue 683.5m / 671.3m)
TATA: -0.05 (NI 15.4m - CFO 75.1m) / TA 1.20b)
Beneish M-Score: -3.49 (Cap -4..+1) = AA
What is the price of USPH shares? As of April 16, 2026, the stock is trading at USD 77.13 with a total of 99,417 shares traded.
Over the past week, the price has changed by -0.09%, over one month by -1.68%, over three months by -12.06% and over the past year by +12.77%.
Is USPH a buy, sell or hold? US Physicalrapy has received a consensus analysts rating of 4.14. Therefore, it is recommended to buy USPH.
  • StrongBuy: 2
  • Buy: 4
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the USPH price?
Analysts Target Price 104 34.8%
US Physicalrapy (USPH) - Fundamental Data Overview as of 14 April 2026
P/E Trailing = 53.8592
P/E Forward = 27.3224
P/S = 1.5036
P/B = 2.4276
P/EG = 2.7314
Revenue TTM = 683.5m USD
EBIT TTM = 87.3m USD
EBITDA TTM = 109.7m USD
Long Term Debt = 152.6m USD (from longTermDebt, last quarter)
Short Term Debt = 52.0m USD (from shortTermDebt, last quarter)
Debt = 425.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 390.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.55b USD (1.16b + Debt 425.7m - CCE 35.6m)
Interest Coverage Ratio = 9.23 (Ebit TTM 87.3m / Interest Expense TTM 9.46m)
EV/FCF = 25.46x (Enterprise Value 1.55b / FCF TTM 61.0m)
FCF Yield = 3.93% (FCF TTM 61.0m / Enterprise Value 1.55b)
FCF Margin = 8.92% (FCF TTM 61.0m / Revenue TTM 683.5m)
Net Margin = 2.25% (Net Income TTM 15.4m / Revenue TTM 683.5m)
Gross Margin = 22.16% ((Revenue TTM 683.5m - Cost of Revenue TTM 532.1m) / Revenue TTM)
Gross Margin QoQ = 20.65% (prev 22.48%)
Tobins Q-Ratio = 1.29 (Enterprise Value 1.55b / Total Assets 1.20b)
Interest Expense / Debt = 0.55% (Interest Expense 2.35m / Debt 425.7m)
Taxrate = 38.66% (5.78m / 15.0m)
NOPAT = 53.5m (EBIT 87.3m * (1 - 38.66%))
Current Ratio = 1.01 (Total Current Assets 140.0m / Total Current Liabilities 139.0m)
Debt / Equity = 0.89 (Debt 425.7m / totalStockholderEquity, last quarter 476.4m)
Debt / EBITDA = 3.56 (Net Debt 390.2m / EBITDA 109.7m)
Debt / FCF = 6.40 (Net Debt 390.2m / FCF TTM 61.0m)
Total Stockholder Equity = 494.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.30% (Net Income 15.4m / Total Assets 1.20b)
RoE = 3.12% (Net Income TTM 15.4m / Total Stockholder Equity 494.5m)
RoCE = 13.49% (EBIT 87.3m / Capital Employed (Equity 494.5m + L.T.Debt 152.6m))
RoIC = 8.15% (NOPAT 53.5m / Invested Capital 656.8m)
WACC = 6.72% (E(1.16b)/V(1.59b) * Re(9.05%) + D(425.7m)/V(1.59b) * Rd(0.55%) * (1-Tc(0.39)))
Discount Rate = 9.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.63%
[DCF] Terminal Value 83.34% ; FCFF base≈63.0m ; Y1≈62.5m ; Y5≈65.4m
[DCF] Fair Price = 78.11 (EV 1.57b - Net Debt 390.2m = Equity 1.18b / Shares 15.1m; r=6.72% [WACC]; 5y FCF grow -1.44% → 3.0% )
EPS Correlation: -11.22 | EPS CAGR: 0.81% | SUE: -0.04 | # QB: 0
Revenue Correlation: 86.32 | Revenue CAGR: 12.19% | SUE: 0.20 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.80 | Chg7d=+0.000 | Chg30d=-0.101 | Revisions Net=+1 | Analysts=6
EPS current Year (2026-12-31): EPS=2.88 | Chg7d=+0.000 | Chg30d=-0.207 | Revisions Net=-1 | Growth EPS=+9.4% | Growth Revenue=+7.4%
EPS next Year (2027-12-31): EPS=3.31 | Chg7d=+0.000 | Chg30d=-0.150 | Revisions Net=+0 | Growth EPS=+15.1% | Growth Revenue=+6.3%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.2% (Discount Rate 9.1% - Earnings Yield 1.9%)
[Growth] Growth Spread = -0.4% (Analyst 6.8% - Implied 7.2%)
External Resources
Dataroma Stockcircle